Alzheimer's disease (AD) is a progressive neurodegenerative disorder with clinical
manifestations appearing in old age, however, the initial stages of this disease may begin …

J. Neurochem.(2012) 120 (Suppl. 1), 62–70. Abstract Alzheimer's disease (AD) is the most
common neurodegenerative disorder leading to dementia. Neuritic plaques are the hallmark …

Abstract β‐Site APP cleaving enzyme 1 (BACE1) is an essential enzyme for the production
of β amyloid. Since we found that injection of interferon‐γ (IFN‐γ) into young mouse brains …

Background It is well established that both cerebral hypoperfusion/stroke and type 2
diabetes are risk factors for Alzheimer's disease (AD). Recently, the molecular link between …

As the most common neurodegenerative disease, therapeutic avenues for the treatment and
prevention of Alzheimer's Disease are highly sought after. The aspartic protease BACE1 is …

Ischemic heart disease (IHD) is among the leading causes of death in developed countries.
Its pathological origin is traced back to coronary atherosclerosis, a lipid-driven immuno …

BACE1 is the protease responsible for the production of amyloid-β peptides that accumulate
in the brain of Alzheimer's disease (AD) patients. BACE1 expression is regulated at the …

β-Site β-amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is the β-secretase in
vivo for processing APP to generate amyloid β protein (Aβ). Aβ deposition in the brain is the …

Deregulation of calcium has been implicated in neurodegenerative diseases, including
Alzheimer's disease (AD). Previously, we showed that saturated free-fatty acid, palmitate …

Alzheimer's disease (AD) currently has over 6million victims in the USA, alone. The recently
FDA approved drugs for AD only provide mild, transient relief for symptoms without …